COVID-19 may have accelerated the adoption of RBQM, but it is the intrinsic benefits that are cementing its continued use.
Patrick Hughes
Advertisement
Patrick Hughes is Co-Founder, Chief Commercial Officer, CluePoints
Articles by Patrick Hughes
What started as an initiative called Risk-Based Monitoring several years ago is now evolving into Risk-Based Quality Management of clinical trials with a much wider impact to the pharma industry.
Advertisement
Latest Updated Articles
- Transitioning from a Risk-Based Monitoring Approach to Risk-Based Quality Management
Published: March 13th 2019 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
2
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
3
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
4
Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
